Senhwa Biosciences announced a clinical collaboration with BeOne Medicines to evaluate CX‑5461 in combination with an antibody‑drug conjugate (ADC) and BeOne’s marketed PD‑1 inhibitor, targeting cold tumors. The PRNewswire release positions the program as an attempt to create a multi‑modal regimen—Senhwa markets CX‑5461 as a transcriptional inhibitor that may sensitize tumors to ADC payloads and checkpoint blockade. The companies will define combination dosing and clinical endpoints in early trials aimed at large global oncology markets; details on timelines and trial sites were not disclosed in the announcement.